Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy

results from the Danish Nationwide DANBIO Registry

Bente Glintborg, Mikkel Ostergaard, Niels Steen Krogh, Martin Dehn Andersen, Ulrik Tarp, Anne Gitte Loft, Hanne M Lindegaard, Mette Holland-Fischer, Henrik Nordin, Dorte Vendelbo Jensen, Christian Holkmann Olsen, Merete Lund Hetland

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

To describe the frequency of treatment switching and outcomes among patients with psoriatic arthritis (PsA) who switched tumor necrosis factor α inhibitor (TNFi) agents in routine care.
OriginalsprogEngelsk
TidsskriftArthritis & Rheumatism
Vol/bind65
Udgave nummer5
Sider (fra-til)1213-1223
ISSN0004-3591
DOI
StatusUdgivet - 2013

Fingeraftryk

Psoriatic Arthritis
Registries
Tumor Necrosis Factor-alpha
Pharmaceutical Preparations

Citer dette

Glintborg, Bente ; Ostergaard, Mikkel ; Krogh, Niels Steen ; Andersen, Martin Dehn ; Tarp, Ulrik ; Loft, Anne Gitte ; Lindegaard, Hanne M ; Holland-Fischer, Mette ; Nordin, Henrik ; Jensen, Dorte Vendelbo ; Olsen, Christian Holkmann ; Hetland, Merete Lund. / Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy : results from the Danish Nationwide DANBIO Registry. I: Arthritis & Rheumatism. 2013 ; Bind 65, Nr. 5. s. 1213-1223.
@article{da927e8eb33d492fbbdd272c16f6dfcd,
title = "Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry",
abstract = "To describe the frequency of treatment switching and outcomes among patients with psoriatic arthritis (PsA) who switched tumor necrosis factor α inhibitor (TNFi) agents in routine care.",
keywords = "Adult, Antirheumatic Agents, Arthritis, Psoriatic, Cohort Studies, Denmark, Drug Substitution, Female, Health Status, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Recovery of Function, Registries, Remission Induction, Survival Rate, Treatment Outcome, Tumor Necrosis Factor-alpha",
author = "Bente Glintborg and Mikkel Ostergaard and Krogh, {Niels Steen} and Andersen, {Martin Dehn} and Ulrik Tarp and Loft, {Anne Gitte} and Lindegaard, {Hanne M} and Mette Holland-Fischer and Henrik Nordin and Jensen, {Dorte Vendelbo} and Olsen, {Christian Holkmann} and Hetland, {Merete Lund}",
note = "Copyright {\circledC} 2013 by the American College of Rheumatology.",
year = "2013",
doi = "10.1002/art.37876",
language = "English",
volume = "65",
pages = "1213--1223",
journal = "Arthritis & Rheumatology",
issn = "2326-5205",
publisher = "Heinemann",
number = "5",

}

Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy : results from the Danish Nationwide DANBIO Registry. / Glintborg, Bente; Ostergaard, Mikkel; Krogh, Niels Steen; Andersen, Martin Dehn; Tarp, Ulrik; Loft, Anne Gitte; Lindegaard, Hanne M; Holland-Fischer, Mette; Nordin, Henrik; Jensen, Dorte Vendelbo; Olsen, Christian Holkmann; Hetland, Merete Lund.

I: Arthritis & Rheumatism, Bind 65, Nr. 5, 2013, s. 1213-1223.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy

T2 - results from the Danish Nationwide DANBIO Registry

AU - Glintborg, Bente

AU - Ostergaard, Mikkel

AU - Krogh, Niels Steen

AU - Andersen, Martin Dehn

AU - Tarp, Ulrik

AU - Loft, Anne Gitte

AU - Lindegaard, Hanne M

AU - Holland-Fischer, Mette

AU - Nordin, Henrik

AU - Jensen, Dorte Vendelbo

AU - Olsen, Christian Holkmann

AU - Hetland, Merete Lund

N1 - Copyright © 2013 by the American College of Rheumatology.

PY - 2013

Y1 - 2013

N2 - To describe the frequency of treatment switching and outcomes among patients with psoriatic arthritis (PsA) who switched tumor necrosis factor α inhibitor (TNFi) agents in routine care.

AB - To describe the frequency of treatment switching and outcomes among patients with psoriatic arthritis (PsA) who switched tumor necrosis factor α inhibitor (TNFi) agents in routine care.

KW - Adult

KW - Antirheumatic Agents

KW - Arthritis, Psoriatic

KW - Cohort Studies

KW - Denmark

KW - Drug Substitution

KW - Female

KW - Health Status

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Recovery of Function

KW - Registries

KW - Remission Induction

KW - Survival Rate

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha

U2 - 10.1002/art.37876

DO - 10.1002/art.37876

M3 - Journal article

VL - 65

SP - 1213

EP - 1223

JO - Arthritis & Rheumatology

JF - Arthritis & Rheumatology

SN - 2326-5205

IS - 5

ER -